HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of interferon-alpha2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study.

Abstract
The safety and potential efficacy of interferon (IFN)-alpha2b were determined for 15 patients during an outbreak of meningoencephalitis due to St. Louis encephalitis (SLE) virus. Clinical and laboratory results were compared with those of 17 untreated patients who were admitted to the same hospital during this nonrandomized preliminary trial. Quadriplegia, quadriparesis, or respiratory insufficiency persisted after the first week of hospitalization, for 11 of 17 untreated patients and for only 2 of 15 treated patients. These complications existed after the second week of hospitalization for 5 of the 17 untreated patients and for 1 of the 15 treated patients. Transient neutropenia and/or mild hepatitis occurred in 11 treated patients. Early initiation of IFN-alpha2b therapy may reduce the severity and duration of complications due to previously untreatable flavivirus meningoencephalitis. A prospective randomized controlled trial is warranted.
AuthorsJames J Rahal, John Anderson, Carl Rosenberg, Teresa Reagan, Lowery Lee Thompson
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 190 Issue 6 Pg. 1084-7 (Sep 15 2004) ISSN: 0022-1899 [Print] United States
PMID15319857 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
Chemical References
  • Antibodies, Viral
  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
Topics
  • Adult
  • Animals
  • Antibodies, Viral (blood)
  • Antiviral Agents (pharmacology, therapeutic use)
  • Cell Line
  • Cell Survival (drug effects)
  • Cricetinae
  • Encephalitis Virus, St. Louis (drug effects, immunology)
  • Encephalitis, St. Louis (complications, drug therapy, epidemiology, virology)
  • Female
  • Hepatitis (etiology)
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (pharmacology, therapeutic use)
  • Leukocyte Count
  • Male
  • Middle Aged
  • Neutropenia (etiology)
  • Pilot Projects
  • Quadriplegia (etiology)
  • Recombinant Proteins
  • Respiratory Insufficiency (etiology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: